Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Epstein−Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas

Open access
Anastasiadou, Eleni, Stroopinsky, Dina, Alimperti, Stella, Jiao, Alan L, Pyzer, Athalia R, Cippitelli, Claudia, Pepe, Giuseppina, Severa, Martina, Rosenblatt, Jacalyn, Etna, Marilena P, Rieger, Simone, Kempkes, Bettina, Coccia, Eliana M, Sui, Shannan J Ho, Chen, Christopher S, Uccini, Stefania, Avigan, David, Faggioni, Alberto, Trivedi, Pankaj, Slack, Frank J · 2019 · Leukemia

Abstract

Cancer cells subvert host immune surveillance by altering immune checkpoint (IC) proteins. Some Epstein-Barr virus (EBV)-associated tumors have higher Programmed Cell Death Ligand, PD-L1 expression. However, it is not known how EBV alters ICs in the context of its preferred host, the B lymphocyte and in derived lymphomas. Here, we found that latency III-expressing Burkitt lymphoma (BL), diffuse large B-cell lymphomas (DLBCL) or their EBNA2-transfected derivatives express high PD-L1. In a DLBCL model, EBNA2 but not LMP1 is sufficient to induce PD-L1. Latency III-expressing DLBCL biopsies showed high levels of PD-L1. The PD-L1 targeting oncosuppressor microRNA miR-34a was downregulated in EBNA2-transfected lymphoma cells. We identified early B-cell factor 1 (EBF1) as a repressor of miR-34a transcription. Short hairpin RNA (shRNA)-mediated knockdown of EBF1 was sufficient to induce miR-34a transcription, which in turn reduced PD-L1. MiR-34a reconstitution in EBNA2-transfected DLBCL reduced PD-L1 expression and increased its immunogenicity in mixed lymphocyte reactions (MLR) and in three-dimensional biomimetic microfluidic chips. Given the importance of PD-L1 inhibition in immunotherapy and miR-34a dysregulation in cancers, our findings may have important implications for combinatorial immunotherapy, which include IC inhibiting antibodies and miR-34a, for EBV-associated cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-018-0178-x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 168

Metadata

Authors
Anastasiadou, E., Stroopinsky, D., Alimperti, S., Jiao, A. L., Pyzer, A. R., Cippitelli, C., Pepe, G., Severa, M., Rosenblatt, J., Etna, M. P., Rieger, S., Kempkes, B., Coccia, E. M., Sui, S. J. H., Chen, C. S., Uccini, S., Avigan, D., Faggioni, A., Trivedi, P., & Slack, F. J.
Venue
Leukemia
Published
2018-06-26
Volume
33
Issue
1
Pages
132-147
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2811453807
Cited by
168
References
4
FWCI
6.99
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epstein−Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. https://app.cochat.ai/papers/10.1038/s41375-018-0178-x
The paper
Anastasiadou, E., Stroopinsky, D., Alimperti, S., Jiao, A. L., Pyzer, A. R., Cippitelli, C., Pepe, G., Severa, M., Rosenblatt, J., Etna, M. P., Rieger, S., Kempkes, B., Coccia, E. M., Sui, S. J. H., Chen, C. S., Uccini, S., Avigan, D., Faggioni, A., Trivedi, P., & Slack, F. J. (2019). Epstein−Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia. https://doi.org/10.1038/s41375-018-0178-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.